Lithium salts are one of the earliest drugs used for AD treatment and can inhibit GSK-3β and reduce Tau phosphorylation and amyloid production but they have poor efficacy for mild AD patient (Hampel et al., 2009). This evidence concerns the gene GSK3B and Alzheimer disease.